Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab plus nab-paclitaxel and gemcitabine for first-line CLDN18.2-positive metastatic pancreatic adenocarcinoma
CTR20220914Phase 2Active
- Sponsor
- Astellas Pharma
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of zolbetuximab in pancreatic adenocarcinoma (PDAC), sponsored by Astellas Pharma. Started Aug 2022; status: active.
02
Drugs
zolbetuximab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20220914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220914.